Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025
Catalyst Pharmaceuticals (NASDAQ: CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has scheduled its second quarter 2025 financial results release for August 6, 2025 after market close.
The company will host a conference call and webcast the following day, Thursday, August 7, 2025, at 8:30 AM ET to discuss financial results and provide a business update. Investors can access the call via US/Canada dial-in (877) 407-8912 or international dial-in (201) 689-8059. The webcast will be available on the Investors section of Catalyst's website with a replay accessible for at least 30 days.
Catalyst Pharmaceuticals (NASDAQ: CPRX), un'azienda biofarmaceutica in fase commerciale specializzata in malattie rare e difficili da trattare, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per il 6 agosto 2025 dopo la chiusura del mercato.
L'azienda terrà una conference call e una webcast il giorno successivo, giovedì 7 agosto 2025 alle 8:30 AM ET, per discutere i risultati finanziari e fornire un aggiornamento sulle attività. Gli investitori potranno partecipare tramite chiamata negli USA/Canada al numero (877) 407-8912 o chiamata internazionale al numero (201) 689-8059. La webcast sarà disponibile nella sezione Investitori del sito web di Catalyst, con la possibilità di riascoltarla per almeno 30 giorni.
Catalyst Pharmaceuticals (NASDAQ: CPRX), una empresa biofarmacéutica en etapa comercial especializada en enfermedades raras y difíciles de tratar, ha programado la publicación de sus resultados financieros del segundo trimestre de 2025 para el 6 de agosto de 2025 después del cierre del mercado.
La compañía realizará una conferencia telefónica y una transmisión en vivo al día siguiente, jueves 7 de agosto de 2025 a las 8:30 AM ET, para discutir los resultados financieros y proporcionar una actualización del negocio. Los inversores podrán acceder a la llamada mediante el número para EE. UU./Canadá (877) 407-8912 o el número internacional (201) 689-8059. La transmisión estará disponible en la sección de Inversores del sitio web de Catalyst, con una repetición accesible por al menos 30 días.
Catalyst Pharmaceuticals (NASDAQ: CPRX)는 희귀 및 치료가 어려운 질환을 전문으로 하는 상업 단계의 생명공학 제약 회사로, 2025년 2분기 재무 실적 발표를 2025년 8월 6일 장 마감 후에 예정했습니다.
회사는 다음 날인 2025년 8월 7일 목요일 오전 8시 30분(동부 시간)에 컨퍼런스 콜과 웹캐스트를 진행하여 재무 결과를 논의하고 사업 현황을 업데이트할 예정입니다. 투자자들은 미국/캐나다 내 전화 (877) 407-8912 또는 국제 전화 (201) 689-8059를 통해 참여할 수 있습니다. 웹캐스트는 Catalyst 웹사이트의 투자자 섹션에서 제공되며, 최소 30일 동안 다시보기 가능합니다.
Catalyst Pharmaceuticals (NASDAQ : CPRX), une société biopharmaceutique en phase commerciale spécialisée dans les maladies rares et difficiles à traiter, a programmé la publication de ses résultats financiers du deuxième trimestre 2025 pour le 6 août 2025 après la clôture du marché.
La société tiendra une conférence téléphonique et une diffusion en direct le lendemain, jeudi 7 août 2025 à 8h30 ET, pour discuter des résultats financiers et fournir une mise à jour sur ses activités. Les investisseurs peuvent accéder à l'appel via le numéro pour les États-Unis/Canada (877) 407-8912 ou le numéro international (201) 689-8059. La diffusion sera disponible dans la section Investisseurs du site web de Catalyst, avec un replay accessible pendant au moins 30 jours.
Catalyst Pharmaceuticals (NASDAQ: CPRX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene und schwer behandelbare Krankheiten spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das zweite Quartal 2025 für den 6. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird am folgenden Tag, Donnerstag, den 7. August 2025, um 8:30 Uhr ET, eine Telefonkonferenz und ein Webcast veranstalten, um die Finanzergebnisse zu besprechen und ein Geschäftsupdate zu geben. Investoren können sich über die US-/Kanada-Einwahlnummer (877) 407-8912 oder die internationale Einwahlnummer (201) 689-8059 einwählen. Das Webcast wird im Investorenbereich der Catalyst-Website verfügbar sein und mindestens 30 Tage lang als Wiederholung abrufbar sein.
- None.
- None.
The Company will Host a Conference Call and Webcast on Thursday, August 7, 2025, at 8:30 AM ET
CORAL GABLES, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its second quarter 2025 financial results after the market close on Wednesday, August 6, 2025.
Catalyst's management team will host a conference call and webcast on Thursday, August 7, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update.
Conference Call & Webcast Details
| Date: | August 7, 2025 |
| Time: | 8:30 AM ET |
| US/Canada Dial-in Number: | (877) 407-8912 |
| International Dial-in Number: | (201) 689-8059 |
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on Catalyst’s website for at least 30 days following the date of the event.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact Mary Coleman, Catalyst Pharmaceuticals, Inc. (305) 420-3200 ir@catalystpharma.com Media Contact David Schull, Russo Partners (858) 717-2310 david.schull@russopartnersllc.com
FAQ
When will Catalyst Pharmaceuticals (CPRX) release Q2 2025 earnings?
How can investors access Catalyst Pharmaceuticals' Q2 2025 earnings call?
Where can I find the replay of Catalyst Pharmaceuticals' Q2 2025 earnings webcast?
What time is Catalyst Pharmaceuticals' Q2 2025 earnings call?
